Linked Life Data

12205692

Source:http://linkedlifedata.com/resource/pubmed/id/12205692

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
17
pubmed:dateCreated
2002-9-2
pubmed:abstractText
For disease indications such as Acquired Immune Deficiency Syndrome (AIDS) and various cancers, randomization to a pure control treatment may be scientifically desirable but not ethically acceptable. Clinicians may insist that the experimental treatment be made available, at least as a rescue medication, for all patients in the control arm. A method for estimating a treatment effect in survival data from randomized clinical trials of this type is developed under an accelerated failure time model. This approach retains all patients in the groups to which they were randomized and is not based on an ad hoc subgroup analysis. By conditioning on having observed patient switch times, this method avoids the need to model patient switching patterns in the analysis. This new approach is evaluated using simulation studies, and is illustrated through analysing data from a Medical Research Council lung cancer trial.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0277-6715
pubmed:author
pubmed:copyrightInfo
Copyright 2002 John Wiley & Sons, Ltd.
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2449-63
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Estimating a treatment effect in survival studies in which patients switch treatment.
pubmed:affiliation
Novartis Pharma AG, Lichtstrasse 35, CH-4056, Basel, Switzerland. mps@reading.ac.uk
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't